SubHero Banner
Text

Qternmet® XR (dapagliflozin/saxagliptin/metformin) – New drug approval

May 3, 2019 - AstraZeneca announced the FDA approval of Qternmet XR (dapagliflozin/saxagliptin/metformin) extended release tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

Download PDF